We serve Chemical Name:5-Bromo-N-cyclohexyl-3-nitropyridin-2-amine CAS:1033202-38-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-Bromo-N-cyclohexyl-3-nitropyridin-2-amine
CAS.NO:1033202-38-8
Synonyms:5-bromo-N-cyclohexyl-3-nitropyridin-2-amine
Molecular Formula:C11H14BrN3O2
Molecular Weight:300.15200
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:70.74000
Exact Mass:299.02700
LogP:4.09310
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-bromo-N-cyclohexyl-3-nitropyridin-2-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-bromo-N-cyclohexyl-3-nitropyridin-2-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-bromo-N-cyclohexyl-3-nitropyridin-2-amine Use and application,5-bromo-N-cyclohexyl-3-nitropyridin-2-amine technical grade,usp/ep/jp grade.
Related News: But the ban from Italy remains, Joseph Wu, Taiwan��s foreign minister, said on Sunday. 5-Bromo-N-cyclohexyl-3-nitropyridin-2-amine manufacturer But the ban from Italy remains, Joseph Wu, Taiwan��s foreign minister, said on Sunday. 5-Bromo-N-cyclohexyl-3-nitropyridin-2-amine supplier She said she revealed her diagnosis in the interest of transparency but in truth really mostly as a shoutout to early diagnosis,” and wanted to “urge women to educate themselves on this disease; to get all the regular screenings and scans that you can; to always listen to your bodies; and of course to ensure that your legitimate medical concerns are not dismissed or diminished. 5-Bromo-N-cyclohexyl-3-nitropyridin-2-amine vendor The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. 5-Bromo-N-cyclohexyl-3-nitropyridin-2-amine factory The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.
